Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Immunocore Holdings (IMCR) Cost of Revenue (2023 - 2025)

Historic Cost of Revenue for Immunocore Holdings (IMCR) over the last 4 years, with Q3 2025 value amounting to $513000.0.

  • Immunocore Holdings' Cost of Revenue rose 1450.89% to $513000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $2.7 million, marking a year-over-year increase of 434.45%. This contributed to the annual value of $2.7 million for FY2024, which is 16335.58% up from last year.
  • Per Immunocore Holdings' latest filing, its Cost of Revenue stood at $513000.0 for Q3 2025, which was up 1450.89% from $1.0 million recorded in Q2 2025.
  • Over the past 5 years, Immunocore Holdings' Cost of Revenue peaked at $1.7 million during Q2 2024, and registered a low of $41000.0 during Q2 2022.
  • In the last 4 years, Immunocore Holdings' Cost of Revenue had a median value of $346000.0 in 2023 and averaged $530692.3.
  • Examining YoY changes over the last 5 years, Immunocore Holdings' Cost of Revenue showed a top increase of 74390.24% in 2023 and a maximum decrease of 7163.12% in 2023.
  • Immunocore Holdings' Cost of Revenue (Quarter) stood at $705000.0 in 2022, then tumbled by 71.63% to $200000.0 in 2023, then skyrocketed by 65.0% to $330000.0 in 2024, then skyrocketed by 55.45% to $513000.0 in 2025.
  • Its Cost of Revenue stands at $513000.0 for Q3 2025, versus $1.0 million for Q2 2025 and $831000.0 for Q1 2025.